NCT00067782已完成3 期
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
Bristol-Myers Squibb1 个研究点 分布在 1 个国家开始时间: 2002年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
- 主要终点
- Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.
研究概览
简要总结
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be on current HIV treatment regimen at least 3 to 6 months prior to study (this must be one protease inhibitor, or ritonavir-boosted protease inhibitor, and two nucleoside reverse transcriptase inhibitors) must be subject's first PI ever received
- •Plasma HIV-1 RNA level < 50 c/mL within 3 to 6 months prior to study start
- •Fasting LDL cholesterol > 130 mg/dL
排除标准
- •WOCBP who do not use effective barrier contraception for any reason
- •Women who are pregnant or breast feeding
- •A life expectancy < 12 months
- •Presence of a newly diagnosed HIV-related OI or any medical condition requiring acute therapy at the time of enrollment
- •Cushing's Syndrome
- •Uncontrolled diabetes mellitus, history of diabetic ketoacidosis or hyperosmolar syndrome
- •Untreated hypothyroidism or hyperthyroidism
- •Nephrotic syndrome or significant proteinuria
- •Obstructive liver disease
- •Active alcohol or substance abuse
- •Proven or suspected acute hepatitis in the 30 days prior to study entry
- •Intractable diarrhea (greater than or equal to 6 loose stools/day for at least 7 consecutive days) within 30 days prior to study start
- •History of acute or chronic pancreatitis
- •Inability to swallow capsules
- •Presence of cardiomyopathy
- •Known history of prolonged QTc interval
- •Any of the following:
- •clinical symptoms potentially related to heart block
- •heart rate < 40 bpm
- •any of the following EKG abnormalities:
- •i) pause length > 3 seconds ii) second or third degree AV heart block iii) QTc interval > 450 msec for males iv) QTc interval > 470 msec for females
- •Fasting serum triglyceride level > 750 mg/dL
- •Any of the following lab values within 2 weeks of starting study drug:
- •serum creatinine greater to or equal to 1.5 times the upper limit of normal
- •total serum lipase greater than or equal to 1.4 times the upper limit of normal
- •liver transaminases greater than or equal to 3 times the upper limit of normal
- •total serum bilirubin greater than or equal to 1.5 times the upper limit of normal
- •Hypersensitivity to any component of the formulation of study drug
- •Use of any lipid-lowering agent within 4 weeks prior or during study
- •Use of a PI-containing ARV regimen prior to entry which is comprised of more than one PI
- •Inclusion of an NNRTI in the PI-containing regimen
- •Prisoners or subjects involuntary incarcerated for treatment of psychiatric or physical illness
研究组 & 干预措施
1
Active Comparator
干预措施: Atazanavir (immediate switch) (Drug)
2
Active Comparator
干预措施: Atazanavir (Week 24 switch) (Drug)
结局指标
主要结局
Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate HypercholesterolemiaHypercholesterolemiaNCT00440154Sanofi206
已完成
2 期
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary CirrhosisPrimary Biliary CirrhosisNCT01865812Intercept Pharmaceuticals27
已完成
2 期
MARS - Monitored Atherosclerosis Regression StudyAtherosclerosisCoronary Artery DiseaseNCT00116870Merck Sharp & Dohme LLC270
已完成
2 期
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaHIV InfectionsNCT00528060French National Agency for Research on AIDS and Viral Hepatitis35
已完成
1 期
Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/TenofovirHIV InfectionsNCT00365339Bristol-Myers Squibb40